Page 321 - Read Online

Page 12 of 15 Chen et al. Hepatoma Res 2018;4:29 I http://dx.doi.org/10.20517/2394-5079.2018.18

33. Bayo J, Real A, Fiore E, Malvicini M, Sganga L, Bolontrade M, Andriani O, Bizama C, Fresno C, Podhajcer O, Fernandez E,
Gidekel M, Mazzolini G, García M. IL-8, GRO and MCP-1 produced by hepatocellular carcinoma microenvironment determine the
migratory capacity of human bone marrow-derived mesenchymal stromal cells without affecting tumor aggressiveness. Oncotarget
2017;8:80235-48.
34. Shao Y, Lin H, Li Y, Lee Y, Chen H, Cheng A, Hsu C. High plasma interleukin-6 levels associated with poor prognosis of patients with
advanced hepatocellular carcinoma. Jpn J Clin Oncol 2017;47:949-53.
35. Hayashi T, Yamashita T, Terashima T, Suda T, Okada H, Asahina Y, Hayashi T, Hara Y, Nio K, Sunagozaka H, Takatori H, Arai K,
Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Serum cytokine profiles predict survival benefits in patients with advanced
hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. BMC Cancer 2017;17:870.
36. Ding Y, Wu Z, Wei Y, Shu L, Peng Y. Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by
diethylnitrosamine. J Cancer Res Clin Oncol 2017;143:821-34.
37. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, Li F, Dewhirst MW, Li CY. Tumor necrosis factor-alpha is a potent endogenous
mutagen that promotes cellular transformation. Cancer Res 2006;66:11565-70.
38. Lu H, Han M, Yuan X, Tursun K, Zhang Y, Li Y, Li Z, Feng S, Zhou L, Pan Z, Wang Q, Han K, Liu S, Cheng J. Role of IL-6-mediated
expression of NS5ATP9 in autophagy of liver cancer cells. J Cell Physiol 2017; doi: 10.1002/jcp.26343.
39. Wu X, Dong L, Lin X, Li J. Relevance of the NLRP3 inflammasome in the pathogenesis of chronic liver disease. Front Immunol
2017;8:1728.
40. Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 2008;18:334-42.
41. Trasino S, Tang X, Jessurun J, Gudas L. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty
liver disease. J Mol Med 2016;94:1143-51.
42. Harvey W, Jurgensen K, Pu X, Lamb C, Cornell K, Clark R, Klocke C, Mitchell K. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) increases human hepatic stellate cell activation. Toxicology 2016;344-346:26-33.
43. Vanegas N, Vernot J. Loss of quiescence and self-renewal capacity of hematopoietic stem cell in an in vitro leukemic niche. Exp
Hematol Oncol 2017;6:2.
44. Han K, Han H, He X, Wang L, Guo X, Zhang X, Chen J, Zhu Q, Nian H, Zhai X, Jiang M. Chemokine CXCL1 may serve as a potential
molecular target for hepatocellular carcinoma. Cancer Med 2016;5:2861-71.
45. Cortes M, Chen M, Stachura D, Liu S, Kwan W, Wright F, Vo L, Theodore L, Esain V, Frost I, Schlaeger T, Goessling W, Daley G, North T.
Developmental vitamin D availability impacts hematopoietic stem cell production. Cell Rep 2016;17:458-68.
46. Jeng K, Jeng C, Jeng W, Chang C, Sheen I. Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of
hepatocellular carcinoma. Oncol Lett 2017;14:1905-10.
47. Kisen GO, Tessitore L, Costelli P, Gordon PB, Schwarze PE, Baccino FM, Seglen PO. Reduced autophagic activity in primary rat
hepatocellular carcinoma and ascites hepatoma cells. Carcinogenesis 1993;14:2501-5.
48. Silvente-Poirot S, Ségala G, Poirot M, Poirot M. Ligand-dependent transcriptional induction of lethal autophagy: a new perspective for
cancer treatment. Autophagy 2018;14:555-7.
49. Mi Y, Xiao C, Du Q, Wu W, Qi G, Liu X. Momordin Ic couples apoptosis with autophagy in human hepatoblastoma cancer cells by
reactive oxygen species (ROS)-mediated PI3K/Akt and MAPK signaling pathways. Free Radic Biol Med 2016;90:230-42.
50. Sun H, Zou S, Candiotti K, Peng Y, Zhang Q, Xiao W, Wen Y, Wu J, Yang J. Octreotide attenuates acute kidney injury after hepatic
ischemia and reperfusion by enhancing autophagy. Sci Rep 2017;7:42701.
51. Zeng Y, Lian S, Li D, Lin X, Chen B, Wei H, Yang T. Anti-hepatocarcinoma effect of cordycepin against NDEA-induced hepatocellular
carcinomas via the PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB pathway in mice. Biomed Pharmacother 2017;95:1868-75.
52. Vangan N, Cao Y, Jia X, Bao W, Wang Y, He Q, Binderiya U, Feng X, Li T, Hao H, Wang Z. mTORC1 mediates peptidoglycan induced
inflammatory cytokines expression and NF-κB activation in macrophages. Microb Pathog 2016;99:111-8.
53. Sui W, Zhang Y, Wang Z, Wang Z, Jia Q, Wu L, Zhang W. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed
to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H 22 murine hepatocarcinoma model. Oncol
Rep 2014;31:2252-60.
54. Zhu Y, Zheng B, Wang H, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin
2017;38:614-22.
55. Yang H, Wang J, Fan J, Zhang Y, Zhao J, Dai X, Liu Q, Shen Y, Liu C, Sun W, Sun Y. Ilexgenin A exerts anti-inflammation and anti-
angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma
growth. Toxicol Appl Pharmacol 2017;315:90-101.
56. Johnson C, Tee A. Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance. Essays Biochem 2017;61:699-710.
57. Chen H, Huang Y, Huang J, Lin L, Wei G. Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/
Akt/NF-κB signaling pathway. Oncol Rep 2017;37:865-70.
58. Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y, Liu J, Huang J, Ge C. A blockade of PD-L1 produced antitumor and antimetastatic effects in
an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther 2017;10:2115-26.
59. Wu L, Wang G, Liu S, Wei J, Zhang S, Li M, Zhou G, Wang L. Synthesis and biological evaluation of matrine derivatives containing
benzo-α-pyrone structure as potent anti-lung cancer agents. Sci Rep 2016;6:35918.
60. Huang Z, Su G, Hu W, Bi X, Zhang L, Wan G. The study on expression of CIAPIN1 interfering hepatocellular carcinoma cell
proliferation and its mechanisms. Eur Rev Med Pharmacol Sci 2017;21:3054-60.
61. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL. Effect of everolimus on survival in
advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57-67.